Status:
COMPLETED
Clinical Use of Stem Cells for the Treatment of Covid-19
Lead Sponsor:
SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi
Collaborating Sponsors:
Istinye University
Regenerative Medicine and Stem Cell Production Center Liv MedCell
Conditions:
Covid19
Pneumonia
Eligibility:
All Genders
40-60 years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is know...
Detailed Description
Introduction: The COVID-19 corona virus epidemic has spread from Wuhan, China to the whole world, and has been declared a pandemic by WHO worldwide. In severe patients, ARDS and multiple organ failur...
Eligibility Criteria
Inclusion
- 40-60 years old male or female
- Confirmed 2019-nCoV infection with RT-PCR Laboratory test
- Confirmed Pneumonia with chest radiography and computer tomography
- and any of the following criteria:
- Shortness of breath (RR ≥30/min)
- Resting finger oxygen saturation 93%
- Arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300MMHG
- Advancing of focus in Pulmonary imaging to \>50% in 24-48 hours
Exclusion
- Those who are not pregnant, breastfeeding and pregnant but who do not take effective contraceptive measures;
- Patients with malignant tumors, other serious systemic diseases and psychosis;
- Informed consent is not given or does not comply with the test requirements.
- Co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus.
- Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus.
- Obstructive HABP / VABP caused by lung cancer or other known causes; Long-term history of use of immunosuppressive agents;
- History of epilepsy and need for continuous anticonvulsant therapy or anticonvulsant therapy taken within 3 years;
- Invasive ventilation
- Shock
- Other organ failures
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04392778
Start Date
April 1 2020
End Date
November 30 2020
Last Update
May 25 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istinye University
Istanbul, Turkey (Türkiye), 34010
2
SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi
Istanbul, Turkey (Türkiye), 34147